Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C402-CD19-CAR in Relapsed or Refractory Large B-cell Lymphoma
NCT06830031Phase 1Recruiting
- Sponsor
- EXUMA Biotech
- Start
- Mar 2025
- Primary completion
- Apr 2029
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of C402-CD19-CAR in diffuse large B-cell lymphoma (DLBCL), sponsored by EXUMA Biotech. Primary endpoints: Maximum Tolerated Dose at 28 days and Adverse Events up to 2 years. Started Mar 2025; status: recruiting.
02
Drugs
C402-CD19-CAR
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06830031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06830031.